NCT04141592 Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease
| NCT ID | NCT04141592 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen Mary University of London |
| Condition | Non-Alcoholic Fatty Liver Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 153 participants |
| Start Date | 2019-03-05 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 153 participants in total. It began in 2019-03-05 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Confirmed non-alcoholic Fatty liver disease (diagnosed clinically, radiologically or histologically) * If diabetic, Diagnosed with Type 2 Diabetes Mellitus OR • Healthy Control: no diagnosis of any liver condition including NAFLD o NAFLD excluded by Fibroscan Controlled Attenuation Parameter (CAP) score of \<222 dB/m Exclusion Criteria: * Unwilling or unable to give informed consent * Type 1 Diabetes Mellitus * Other form of liver disease (other than NAFLD) o Viral hepatitis, Auto-immune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, haemochromatosis, Sarcoidosis, cystic fibrosis, sickle cell disease * Taking medication associated with liver dysfunction (except methotrexate) * Auto-immune disease which in the investigator's opinion may confound immune profiling * Concomitant immunosuppressive medications (except methotrexate, short course oral steroids or inhaled corticosteroids) * Currently pregnant * Any major organ transplant (excluding corneal or hair transplant) * Regular alcohol intake greater than 14 units a week for female participants and 21 units a week for male participants
Contact & Investigator
William Alazawi, MD Phd
PRINCIPAL INVESTIGATOR
Queen Mary University of London
Frequently Asked Questions
Who can join the NCT04141592 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Alcoholic Fatty Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04141592 currently recruiting?
Yes, NCT04141592 is actively recruiting participants. Contact the research team at w.alazawi@qmul.ac.uk for enrollment information.
Where is the NCT04141592 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT04141592 clinical trial?
NCT04141592 is sponsored by Queen Mary University of London. The principal investigator is William Alazawi, MD Phd at Queen Mary University of London. The trial plans to enroll 153 participants.